Osteoprotegerin/TNFRSF11B Antibody (69146) [Unconjugated]

In the presence of the metabolic inhibitor actinomycin D (0.5 µg/mL), Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (Catalog # 805-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (50 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti‑Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB805). The ND50 is typically 0.15-0.3 µg/mL.

Methotrexate decreases mRNA and protein expression of RANKL and RANK in rheumatoid arthritis synovial-derived fibroblasts. A significant decrease in the receptor activator of the NF-kappa B ligand (RANKL) mRNA levels (A) with no changes in osteoprotegerin (OPG) mRNA levels (B) in the presence of methotrexate (MTX). Representative blots and graphs showing decrease of cellular RANKL protein expression (C and D) with no changes in the cellular OPG expression (C and E) in the presence of MTX. Decrease of soluble RANKL protein expression (F) with no changes in the soluble OPG expression (G) in the presence of MTX, where results are quantified by enzyme-linked immunosorbent assay. *p<0.05. Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar4398), licensed under a CC-BY license. Not internally tested by R&D Systems.

OPG exerts protective effects on cartilage catabolism.A. OPG/RANKL mRNA ratio in IL1-beta stimulated bone explants cultured with estradiol at 0.01 µM (E-8) and 1 µM (E-6), and with pamidronate (PAM). The graph represents the mRNA ratio to controls in 3 different experiments. B. Effect of OPG blockade by a neutralizing antibody (OPG-ab) on ARGS374 sequences expression in supernatants of cartilage explants cultured with conditioned bone media. Image of a representative Western blot, and the graph shows the mean quantifications ± SEM of 4 different experiments. Quantification was done on the 50 kDa bands. *: p<0.05. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0033543), licensed under a CC-BY license. Not internally tested by R&D Systems.

Methotrexate decreases expression of RANKL and RANK in the rheumatoid synovium of early-untreated rheumatoid arthritis. Brown immunohistochemistry (diaminobenzidine) staining of cell surface markers in synovial biopsies of early rheumatoid arthritis (RA). Synovial receptor activator of the NF-kappa B ligand (RANKL) expression in early, untreated RA synovium (A) decreased significantly following 8 weeks of methotrexate (MTX) treatment (B), as evaluated by semi-quantitative double-blind microscopic analysis (C). Synovial receptor activator of NF-kappa B (RANK) expression in early, untreated RA synovium (D) decreased significantly following 8 weeks of MTX treatment (E), as evaluated by semi-quantitative double-blind microscopic analysis (F). Synovial osteoprotegerin (OPG) expression in early, untreated RA (G) is not changed following 8 weeks (H) of MTX treatment, as evaluated by semi-quantitative double-blind microscopic analysis (I). *p<0.05. Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar4398), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: B/N
• Clone: 69146
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Osteoprotegerin/TNFRSF11B Antibody (69146) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
  Glu22-Leu401
  Accession # AAB53709
• Specificity: Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Osteoprotegerin is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF11B
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.15-0.3 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteoprotegerin/TNFRSF11B Antibody (69146) [Unconjugated]

• OCIF
• OCIFMGC29565
• OPG
• OPGtumor necrosis factor receptor superfamily member 11B
• Osteoclastogenesis inhibitory factor
• Osteoprotegerin
• TNFRSF11B
• TR1
• tumor necrosis factor receptor superfamily, member 11b

Background

Osteoprotegerin is a member of the TNF receptor superfamily expressed by many cell types. It exists in soluble monomeric and dimeric forms as a decoy receptor for its ligands, TRANCE and TRAIL. Osteoprotegerin functions as an antagonist to RANKL-induced osteoclastogenesis and bone resorption.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Osteoprotegerin/TNFRSF11B Antibody (MAB805)(10)

Publications using MAB805

• Katerina Chatzidionysiou, Alexandra Circiumaru, Bence Rethi, Vijay Joshua, Marianne Engstrom, Aase Hensvold et al. Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL RMD Open 6/9/2021 [PMID: 34112702]
• Joshua S. McLane, Lee A. Ligon Stiffened Extracellular Matrix and Signaling from Stromal Fibroblasts via Osteoprotegerin Regulate Tumor Cell Invasion in a 3-D Tumor in Situ Model Cancer Microenvironment 12/1/2016 [PMID: 27654881]
• Jiao Jiao, Li-na Niu, Qi-hong Li, Fa-ming Chen, Wei Zhao, Jun-jie Li et al. Biphasic silica/apatite co-mineralized collagen scaffolds stimulate osteogenesis and inhibit RANKL-mediated osteoclastogenesis Acta Biomaterialia 6/1/2015 [PMID: 25792280]
• Shankar Revu, Petra Neregård, Erik af Klint, Marina Korotkova, Anca Irinel Catrina Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate Arthritis Research & Therapy 12/3/2013 [PMID: 24295447]
• Thomas Funck-Brentano, Hilène Lin, Eric Hay, Marie-Dominique Ah Kioon, Corinne Schiltz, Didier Hannouche et al. Targeting Bone Alleviates Osteoarthritis in Osteopenic Mice and Modulates Cartilage Catabolism PLoS ONE 3/14/2012 [PMID: 22432033]
• Irene Zinonos, Agatha Labrinidis, Michelle Lee, Vasilios Liapis, Shelley Hay, Vladimir Ponomarev et al. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo Journal of Bone and Mineral Research 7/29/2017 [PMID: 20818644]
• Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol. Cancer Ther., 2007-12-07;6(12):3219-28. 2007-12-07 [PMID: 18065493] (Neutralization, Human)
• Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum., 2006-05-01;54(5):1463-72. 2006-05-01 [PMID: 16646024] (IHC, Western Blot, Human)
• Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelao W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin. Exp. Rheumatol., 2005-03-01;23(2):185-92. 2005-03-01 [PMID: 15895888] (IHC, Human)
• Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J. Rheumatol., 2005-04-01;32(4):713-20. 2005-04-01 [PMID: 15801030] (IHC, Human)

Bioinformatics

• Gene Symbol: TNFRSF11B
• Uniprot:
  • AAB53709()